Compare ARK Genomic Revolution ETF (ARKG) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Franklin Resources, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41, while Franklin Resources, Inc. trades at $33.64 (market cap $17.41B). The key difference: Franklin Resources, Inc. pays a 3.94% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | BEN | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $43.57 | $34.44 |
52-Week Low | $23.09 | $21.18 |
Market Cap | — | $17.41B |
Enterprise Value | — | $29.23B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Franklin Resources (BEN) trades at $33.50, down 0.53% on the day, with a bullish technical outlook from moving averages and a consensus price target of $34.17. The company reported Q1 2026 EPS of $0.71, beating expectations of $0.55, and maintains strong profitability with an 80.72% gross margin. Recent news highlights its inclusion in dividend stock lists and a Zacks upgrade to Strong Buy on June 23, 2026, amid steady asset growth to $1.79 trillion AUM in June.
BEN presents a mixed outlook with solid earnings beats and dividend appeal offset by weak cash flow trends and modest growth. Upside is supported by analyst optimism and technical momentum, but risks include net cash outflows and competitive pressures in asset management. The stock's valuation at a P/E of 25.57 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
